THU0439 MORE OBESITY AND HIGHER SERUM URIC ACID IN EARLY-ONSET GOUT PATIENTS IN SOUTH CHINA
Background: Gout incidence increases in a linear fashion with age until 70 years. It was reported that there was a trend of earlier gout onset. Few studies about clinical features of early-onset gout in China are reported. Objectives: To investigate the characteristics of early-onset gout in south China. Methods: Patients with primary gout were recruited between June 2012 and December 2016. Face to face interview was carried out to collect demographic information, clinical characteristics of gout and comorbid diseases. The patients with gout onset before age 30 were defined as early-onset group. The other gout patients were enrolled as control group. Results: (1) Five hundred and one gout patients were recruited, including 99 (19.8%) in the early-onset group and 402 (80.2%) in the control group. The onset age of the early-onset group was 24.2±5.8 (range 14-30) and the control group was 51.7±13.9 (range 31-84). There was no significant difference of gout duration between early-onset group and control group (P<0.05, Table 1 ).
(2) Compared with the control group, the early-onset group presented lower frequency of flare in last year, higher serum uric acid and higher proportion of sUA>10mg/dl (P<0.05, Table 1 ). Body mass index (BMI) and prevalence of obesity were higher in the early-onset group (P<0.05, Table 1 ). The early-onset group exhibited lower prevalence of hypertension, diabetic mellitus, urolithiasis and chronic kidney disease (CKD) (P<0.05, Background: Data on the risk of venous thromboembolism (VTE, including deep venous thrombosis and pulmonary embolism) in patients with gout are scarce. Objectives: 1) To estimate the overall risk of VTE in an incident gout cohort; 2) To estimate the temporal trends of VTE before and after gout diagnosis compared with the general population.
Methods:
We conducted a matched cohort study using a population based administrative health database that includes all outpatient visits, hospital admissions, vital statistics, and dispensed medications for all residents in British Columbia, Canada. Gout cases were defined using one ICD-9/10 code (274/M10) from a physician or hospital visit. To ensure incident gout, we required that all cases have ≥10 years of prior registration without a gout diagnosis. Gout cases were matched 1:1 with controls on age, sex, and cohort entry time. Prior VTE events were excluded after matching. VTE was defined using ICD-9/ICD-10 codes plus use of oral anti-coagulant. We calculated incidence rate ratios (IRRs) and age, sex, and entry time matched multivariable hazard ratios (HRs) for the risk of VTE. Sensitivity analyses were conducted to assess for unmeasured confounders (e.g., obesity). Results: Among 105,307 individuals with newly diagnosed gout (61% male, mean age of 58 yrs), we observed 1,212 VTE events (mean follow-up time of 5.3 yrs). The fully adjusted HR was 1.27 (95% CI, 1.16-1.39) ( Table 1) . Our results remained significant in the sensitivity analyses (OR of 2.0 between gout and unmeasured confounder and a 50% prevalence for obesity). There were 437 incident VTE events within 3 yrs prior to the gout diagnosis. Compared to controls, during the 3rd, 2nd, and 1st yrs before gout diagnosis, the fully adjusted HRs for VTE in patients with imminent gout were 1.51, 1.58 and 1.73. The corresponding HRs in the 1st, 2nd, 3rd, 4th, and 5th yrs after gout diagnosis were 1.54, 1.39, 1.38, 1.37, and 1.32, respectively. Background: Joint deposits of monosodium urate (MSU) crystals in asymptomatic hyperuricemia (AH) may associate with more severe forms of atherosclerosis [1] . It likely relates with crystal-driven subclinical inflammation, a phenomenon well described in gout [2] but to date not assessed in AH. Objectives: To assess the synovial fluid (SF) leukocytes count in patients with AH depending on the presence of crystals. Methods: Consecutive patients with AH were selected from nephrology clinics. Hyperuricemia threshold was established at serum uric acid (SUA) ≥7mg/dL; those on current urate-lowering therapy were excluded. Ultrasound (US) of knees, ankles and first metatarsophalangeal joints was performed blinded to clinical and laboratory data, in order to perform US-guided aspiration and obtain SF samples. These samples were analyzed in fresh by two observers, using a compensated polarized light microscope equipped with two viewing stations. The second observer was in addition unaware of US findings. The presence of leukocytes and crystals was established by consensus. SF leukocyte count was performed using a Neubauer counting camera. Mann-Whitney's U and Kruskal-Wallis' H were used to compare difference in leukocyte counts between groups. Results: To end of January 2017, 30 patients have been assessed, with SF samples available from 27 (three showed no joint effusion at US). Median age was 70 years (p25-75 59.8-75.5), and 16 of them (60%) were males. Median (p25-75) SUA and estimated glomerular filtration rate were 8.1 mg/dL (7.6-8.5) and 37.0 mL/min (31.0-47.5), respectively. Seven (25%) were on diuretics. After microscopy evaluation, MSU crystals were found in four patients (14.8%), calcium pyrophosphate (CPP) crystals in five (18.5%), and no crystals in 18 (66.7%). (138-540) in MSU group; 60/mm 3 (50-235) in CPP group; and 30/mm 3 (10-53) in those with no crystal at SF. A statistically significant difference was found between the three groups (p=0.001), and comparing MSU crystals and no crystals groups (p<0.001); no difference was found between MSU and CPP groups (p=0.111).
Conclusions:
In a preliminary report, MSU crystal deposition in patients with AH leads to higher SF leukocyte count, indicating low-grade inflammation. Despite low numbers and being an ongoing study, this significant finding might contribute to explain the severe atherosclerosis data recently reported in AH patients with silent crystal deposits. Background: Sub-optimal quality of care for gout, the most common inflammatory arthritis, has called for novel models to improve care and outcomes of patients. Objectives: Our objective was to evaluate the feasibility of the "Virtual Gout Clinic Study" (VGCS) a collaborative approach to gout management involving rheumatology, pharmacy, and dietetics that take advantage of eHealth, namely, shared access of electronic medical records (EMRs), to support this unique, decentralized model of care. Methods: Design: We conducted a 1-year, proof-of-concept, longitudinal observational study with a target of 30 patients. Eligibility: Patients with gout were eligible if they were: 1) seen in 1 of 4 rheumatology practices with 8 rheumatologists participating across British Columbia, Canada; 2) experienced ≥1 flare in the past year; 3) have a serum uric acid (SUA) level ≥360 μmol/L within the previous 2 months. Follow-up: Within the VGCS, patients receive follow-up with their rheumatologist on an as needed-basis, monthly telephone consults from the study pharmacist, and 1 telephone consult with the dietician. In this decentralized model of care, health care professionals are not co-located but have access to the patient's EMR to facilitate remote communication and collaboration. Outcomes: Prospective data was collected at baseline, 3, 6, and 12 months. The primary outcome measure was SUA at 12-months, specifically below recommended target level of 360 μmol/L. Secondary outcomes included patient reported outcome measures including the Compliance Questionnaire Rheumatology, Health Assessment Questionnaire Disability Index, and EQ-5D, as well as information on interventions provided within the VGCS. Results: Overall, 33 individuals with gout participated in the VGCS. There were 22 males (88%) and mean age was 60.8±15.3 years. 29, 28, and 25 patients have completed follow-up at 3, 6, and 12 months respectively. At baseline, 22 (67%) patients were prescribed urate-lowering therapy (ULT; 21 with allopurinol and 1 with febuxostat). The remaining 11 patients initiated ULT during the study period. Figure 1 shows mean SUA decreased over baseline, 3, 6, and 12 months from 451 μmol/L, 367 μmol/L, 356 μmol/L, and 364 μmol/L, respectively, with 67% of patients having SUA <360 μmol/L at 12 months. A total of 126 pharmacist and 24 dietician consults have been provided. Pharmacist interventions included: uptritration of allopurinol dosage for 15 patients, restarting of ULT for 4 nonadherent patients, discontinuation of unnecessary medications for 12 patients, and renewals of prescription medications using solely electronic communications for 4 patients. Conclusions: These findings provide evidence for the feasibility and effectiveness of the VGCS. With respect to feasibility, we successfully established the shared EMR framework between rheumatologists and study pharmacist and dietitian and demonstrated utility with respect to facilitating communication and collaborative
